ArticleCancer chemotherapy and pharmacology2009
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Article in Cancer chemotherapy and pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Decreased Expression of LAMB3 Is Associated with Esophageal Cancer Stem Cell Formation.Advanced pharmaceutical bulletin · 2022Article
- Tricking enzymes in living cells: a mechanism-based strategy for design of DNA topoisomerase biosensors.Journal of nanobiotechnology · 2021Article
- MicroRNA-9-5p increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating high mobility group A2 expression.Oncology letters · 2021Article
- Long Non-Coding RNA: A Potential Strategy for the Diagnosis and Treatment of Colorectal Cancer.Frontiers in oncology · 2021Review
- Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression.Nature communications · 2020Article
- Bioinformatics Analysis of Prognostic miRNA Signature and Potential Critical Genes in Colon Cancer.Frontiers in genetics · 2020Article
- The correlation between DNA mismatch repair status and the clinicopathological and molecular features of Chinese sporadic colorectal cancer.Translational cancer research · 2020Article
- Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.Journal of medicinal chemistry · 2019Article
- Spica Prunellae Extract Enhances Fluorouracil Sensitivity of 5-Fluorouracil-Resistant Human Colon Carcinoma HCT-8/5-FU Cells via TOP2BioMed research international · 2019Article
- Over-expression of TOP2A as a prognostic biomarker in patients with glioma.International journal of clinical and experimental pathology · 2018Article
- Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.Digestive diseases and sciences · 2017Article
- Identification of potential key genes associated with glioblastoma based on the gene expression profile.Oncology letters · 2017Article
- Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.BMC cancer · 2017Article
- Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.Oncogene · 2016Article
- Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.Molecular oncology · 2015Article
- Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.The oncologist · 2015Article
- Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.British journal of cancer · 2014Article
- Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Frontiers in oncology · 2013Review
- Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.Journal of translational medicine · 2013Article
Corrections and comments
- Erratum issuedArapogiannis, George [corrected to Agrogiannis, George]; Patsouris, Efstathios [corrected to Patsouris, Efstratios]
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHuman DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and outcome after chemotherapy in primary and relapsed colorectal cancer. PATIENTS AND
methodsPatients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study. All had undergone surgical resection of the primary tumor and received post-operatively 5-FU-based (5FU + Leucovorin, Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue was collected at the initial operation from the primary tumor and at the time of recurrence (during the second operation following chemotherapy). All tissue samples were analyzed for levels of expression of both topo-I and topo-IIa using standard three-step immunohistochemistry on paraffin sections.
resultsForty patients were included. Levels of expression of topo-I and topo-II were higher in malignant cells from tumor recurrences compared to primary tumors (P = 0.0001 for both). There was a statistically significant positive relationship between patients age and levels of topo-I (P = 0.011) and topo-II (P = 0.011) expression.
conclusionsThe study results reported here underscore the role of topoisomerase expression in colorectal cancer and suggest a potential role in tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.